Filtered By:
Cancer: Ovarian Cancer

This page shows you your search results in order of date. This is page number 19.

Order by Relevance | Date

Total 759 results found since Jan 2013.

LncRNA HOTAIR regulates anoikis-resistance capacity and spheroid formation of ovarian cancer cells by recruiting EZH2 and influencing H3K27 methylation.
In conclusion, HOTAIR enhances the anoikis resistance and spheroid forming ability of ovarian cancer cells by recruiting EZH2 and influencing H3K27 methylation that may contribute to migration, invasion, and chemoresistance of ovarian cancer cells. PMID: 33502891 [PubMed - as supplied by publisher]
Source: Neoplasma - January 28, 2021 Category: Cancer & Oncology Authors: Dai ZY, Jin SM, Luo HQ, Leng HL, Fang JD Tags: Neoplasma Source Type: research

CPEB4-Promoted Paclitaxel Resistance in Ovarian Cancer In Vitro Relies on Translational Regulation of CSAG2
Conclusion: This study suggests that the drug-resistant protein CSAG2 is translationally induced by CPEB4, which underlies CPEB4-promoted paclitaxel resistance in ovarian cancer in vitro. Thus, interfering CPEB4/CSAG2 axis might be of benefit to overcome paclitaxel-resistant ovarian cancer.
Source: Frontiers in Pharmacology - January 13, 2021 Category: Drugs & Pharmacology Source Type: research

MicroRNA-18a-5p Suppresses Tumor Growth via Targeting Matrix Metalloproteinase-3 in Cisplatin-Resistant Ovarian Cancer
Cumulating evidence indicates that dysregulation of microRNAs (miRNAs) plays a central role in the initiation, progression, and drug resistance of cancer cells. However, the specific miRNAs contributing to drug resistance in ovarian cancer cells have not been fully elucidated. Aimed to identify potential miRNAs involved in platinum resistance, we performed a miRNA expression profile in cisplatin-sensitive and cisplatin-resistant ovarian cancer cells, and we found several differentially abundant miRNAs in the pair of cell lines. Notably, miR-18a-5p (miR-18a), a member of the oncogenic associated miR-17-92 cluster, was decre...
Source: Frontiers in Oncology - December 17, 2020 Category: Cancer & Oncology Source Type: research

Cancers, Vol. 12, Pages 3734: HDAC6 Degradation Inhibits the Growth of High-Grade Serous Ovarian Cancer Cells
This study investigated HDAC6 tumor expression by immunohistochemistry in high-grade serous ovarian cancer (HGSOC) tissue samples and a meta-analysis of HDAC6 gene expression in ovarian cancer from publicly available data. The pharmacological activity of HDAC6 inhibition was assessed in a patient-derived model of HGSOC. HDAC6 was found to be highly expressed in HGSOC tissue samples and in the patient-derived HGSOC cell lines where higher HDAC6 protein and gene expression was associated with a decreased risk of death (hazard ratio (HR) 0.38, (95% confidence interval (CI), 0.16–0.88; p = 0.02); HR = 0.88 (95% C...
Source: Cancers - December 11, 2020 Category: Cancer & Oncology Authors: Ahlam Ali Fengyu Zhang Aaron Maguire Tara Byrne Karolina Weiner-Gorzel Stephen Bridgett Sharon O ’Toole John O ’Leary Caitlin Beggan Patricia Fitzpatrick Amanda McCann Fiona Furlong Tags: Article Source Type: research

ΜiR-182-5p functions as a tumor suppressor to sensitize human ovarian cancer cells to cisplatin through direct targeting the cyclin dependent kinase 6 (CDK6).
CONCLUSIONS: miR-182-5p plays a tumor suppressive role in cisplatin resistance via direct targeting the CDK6, showing miR-182-5p-CDK6 axis as a promising therapeutic target against chemoresistant ovarian cancer. PMID: 33277846 [PubMed - as supplied by publisher]
Source: Journal of B.U.ON. - December 7, 2020 Category: Cancer & Oncology Tags: J BUON Source Type: research

Lidocaine inhibits the metastatic potential of ovarian cancer by blocking NaV1.5 ‐mediated EMT and FAK/Paxillin signaling pathway
This study aims to investigate whether lidocaine inhibits the malignancy of ovarian cancer through NaV1.5 blockage. Human ovarian cancer, its metastatic cancer and normal ovarian tissues were probed with anti ‐NaV1.5 antibodyin situ. Human ovarian cancer A2780 and SKOV3 cells were cultured and their growth, epithelial ‐mesenchymal transition (EMT), migration, and invasion in the presence or absence of lidocaine together with underlying molecular mechanisms were assessed. Murine syngeneic ovarian cancer (ID8) model was also used to determine the chemotherapeutic efficiency of cisplatin in combination with lidoca ine. Th...
Source: Cancer Medicine - December 6, 2020 Category: Cancer & Oncology Authors: Chang Liu, Ming Yu, Yi Li, Hao Wang, Chuanya Xu, Xiaoqing Zhang, Min Li, Hongyan Guo, Daqing Ma, Xiangyang Guo Tags: ORIGINAL RESEARCH Source Type: research

IL-17A/lL-17RA reduces cisplatin sensitivity of ovarian cancer SKOV3 cells by regulating autophagy.
CONCLUSIONS: IL-17A/IL-17RA can decrease chemosensitivity of SKOV3 cells to DDP by upregulating DDP-induced autophagy. PMID: 33243748 [PubMed - in process]
Source: Journal of Southern Medical University - November 29, 2020 Category: Universities & Medical Training Authors: Wang L, Zhang X, Wang L, Wang B, Zhang J, Li Y Tags: Nan Fang Yi Ke Da Xue Xue Bao Source Type: research

Paclitaxel increases sensitivity of SKOV3 cells to hyperthermia by inhibiting heat shock protein 27.
Abstract Hyperthermic intraperitoneal chemotherapy (HIPEC) is a promising treatment strategy for patients with peritoneal metastasis of ovarian cancer. Heat shock proteins (HSPs) play an important role in cellular stress during HIPEC treatment. The aim of the present study was to investigate whether paclitaxel can exert antitumor effects by inhibiting heat shock protein 27 (HSP27) expression during HIPEC treatment. Cell viability was detected by CCK8 assay. We used Western blot analysis to detect HSP27 expression under hyperthermia conditions with or without paclitaxel in SKOV3 cells. To further examine the role o...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - October 24, 2020 Category: Drugs & Pharmacology Authors: Kong XX, Jiang S, Liu T, Liu GF, Dong M Tags: Biomed Pharmacother Source Type: research

Impact of mitochondrial transcription factor A expression on the outcomes of ovarian, endometrial and cervical cancers.
Authors: Hu W, Ma SL, Liu LL, Zhu YH, Zeng TT, Li Y, Guan XY Abstract Gynecologic cancers, including endometrial, ovarian, and cervical cancers, are the leading causes of cancer-related mortality in women worldwide. Mitochondrial transcription factor A (TFAM) has been demonstrated playing critical roles in the development of tumors. However, the clinical relationship of TFAM expression in gynecologic cancers requires further clarification. Our results showed gynecologic cancer cells are highly expressed TFAM in both protein and RNA levels compared to normal cells. The TCGA dataset revealed that TFAM gene expression...
Source: American Journal of Translational Research - October 13, 2020 Category: Research Tags: Am J Transl Res Source Type: research

GSE153839 RNA sequencing (RNA-SEQ) of RECQL4 knockdown by siRNA in ovarian cancer cells
Contributors : Li Guo ; Yingwei LiSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe high frequency of somatic copy number alterations, as opposed to point mutations, is considered a unique feature of high-grade serous ovarian carcinoma (HGSOC). Amplification-dependent overexpression of RECQL4, which participates in DNA replication and repair, mediates the development of various cancers, but its pathobiological and clinical roles are poorly understood. Here, using bioinformatics analysis, RECQL4 amplification was found to occur in 27% of HGSOC samples in the TCGA cohort. RECQL4 was f...
Source: GEO: Gene Expression Omnibus - October 13, 2020 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

GSK-3 β mediates the effects of HNF-1β overexpression in ovarian clear cell carcinoma.
In conclusion and to the best of our knowledge, the current study was the first to determine that GSK-3β is a target gene of HNF-1β. In addition, the results of the present study revealed the novel HNF-1β-GSK-3β-p-NFκB pathway, occurring in response to DNA damage. Targeting this pathway may therefore represent a putative, novel, anticancer strategy in patients with OCCC. PMID: 33005248 [PubMed]
Source: Experimental and Therapeutic Medicine - October 4, 2020 Category: General Medicine Tags: Exp Ther Med Source Type: research

β-arrestin 2 Is a Prognostic Factor for Survival of Ovarian Cancer Patients Upregulating Cell Proliferation
Establishing reliable prognostic factors as well as specific targets for new therapeutic approaches is an urgent requirement in advanced ovarian cancer. For several tumor entities, the ubiquitously spread scaffold protein β-arrestin 2, a multifunctional scaffold protein regulating signal transduction and internalization of activated G protein-coupled receptors (GPCRs), has been considered with rising interest for carcinogenesis. Therefore, we aimed to elucidate the prognostic impact of β-arrestin 2 and its functional role in ovarian cancer. β-arrestin 2 expression was analyzed in a subset of 156 samples of ovarian cance...
Source: Frontiers in Endocrinology - September 17, 2020 Category: Endocrinology Source Type: research

Cancers, Vol. 12, Pages 2556: Impact of Wnt/ β-Catenin Inhibition on Cell Proliferation through CDC25A Downregulation in Soft Tissue Sarcomas
Cancers, Vol. 12, Pages 2556: Impact of Wnt/β-Catenin Inhibition on Cell Proliferation through CDC25A Downregulation in Soft Tissue Sarcomas Cancers doi: 10.3390/cancers12092556 Authors: Esther Martinez-Font Marina Pérez-Capó Rafael Ramos Irene Felipe Carmen Garcías Pablo Luna Josefa Terrasa Javier Martín-Broto Oliver Vögler Regina Alemany Antònia Obrador-Hevia The Wnt signaling pathway is an important cellular mechanism for regulating differentiation processes as well as cell cycle events, and different inhibitors of this pathway, for example, PRI-724, are showing promising results in cl...
Source: Cancers - September 7, 2020 Category: Cancer & Oncology Authors: Esther Martinez-Font Marina P érez-Capó Rafael Ramos Irene Felipe Carmen Garc ías Pablo Luna Josefa Terrasa Javier Mart ín-Broto Oliver V ögler Regina Alemany Ant ònia Obrador-Hevia Tags: Article Source Type: research

Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer.
Authors: Lara OD, Bayraktar E, Amero P, Ma S, Ivan C, Hu W, Wang Y, Mangala LS, Dutta P, Bhattacharya P, Ashizawa AT, Lopez-Berestein G, Rodriguez-Aguayo C, Sood AK Abstract BACKGROUND: Adaptor proteins such as growth factor receptor-bound protein-2 (Grb2) play important roles in cancer cell signaling. In the present study, we examined the biological effects of liposomal antisense oligodeoxynucleotide that blocks Grb2 expression (L-Grb2) in gynecologic cancer models. MATERIALS AND METHODS: Murine orthotopic models of ovarian (OVCAR5 and SKOV3ip1) and uterine (Hec1a) cancer were used to study the biological effe...
Source: Oncotarget - August 13, 2020 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Hypoxia Alters Epigenetic and N-Glycosylation Profiles of Ovarian and Breast Cancer Cell Lines in-vitro
Conclusions: These glycan changes are known to be integral to cancer cell survival and metastases, suggesting a possible mechanism of action, linking GATA2 and 3, and invasiveness of both ovarian and TNBC cells in vitro.
Source: Frontiers in Oncology - July 28, 2020 Category: Cancer & Oncology Source Type: research